The Next Hot Biotech Stock… Can It Beat the Biotech Index?

Biogen (Nasdaq: BIIB) rose as much as 300% in the last five years and if you were in on it, you did well.  But this biotech stock could show that kind of results in just a matter of a few months…. You’ve probably read about the massive gains already in this sector and unless you’re brain dead, you’ll want to know about the next hot biotech stock.

Investors have been climbing on board and the stock has been going nowhere but up…

The Washington Post says, “this industry could be bigger than the NFL by 2020.”  And in case you’re wondering that’s $35 BILLION compared to $10 BILLION for the NFL.

Are your juices flowing yet?   They should be.  HERE’S WHY…

While there’s oodles of cash driving this industry this biotech stock is one that is going to bolt!

In the last month the SPDR S&P Biotech ETF (XBI) is off more-than 5% – while Vitality Biopharma VBIO HAS NEARLY DOUBLED IN PRICE.

We’re featuring one of the hottest biotech stocks out there that’s grabbing investors’ attention, Vitality Biopharma VBIO and for no small reason.  Read on…

Vitality Biopharma VBIO is developing proprietary cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis.

Vitality Biopharma VBIO has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream.

WATCH THIS VIDEO!  This is not some lame pot deal!

WANT TO KNOW MORE?

Don’t be brain dead… this is NOT some blue sky pitch and clinical trials support that.

There is increasing recognition and acceptance from physicians and researchers that there may be vast therapeutic potential for cannabinoids, and especially cannabidiol (“CBD”), which is not mind-altering.

Cannabidiol Clinical Trials

Inflammatory Bowel Disease
Muscle spasticity (in Multiple Sclerosis)
Epilepsy
Neuropathic Pain
Schizophrenia
Huntington’s Disease

Serious Unmet Needs in IBD and MS

Cannabinoids have been demonstrated to help Crohn’s disease patients enter into remission, and large clinical studies have shown that 75-85% of inflammatory bowel disease patients have improvement in abdominal pain and abdominal cramping (Storr et al., Inflammatory Bowel Diseases, 2014)

80% of MS patients have muscle spasticity, a common symptom of MS, which can be treated by a 50-50 blend of THC/CBD, but current oromucosal sprays are a suboptimal delivery method

Current immunomodulatory drugs treat symptoms or reduce immune attack, but do not reverse neurological or functional damage.  Cannabidiol has demonstrated regenerative effects in preclinical studies and due to relatively little toxicity may be used in combination with other agents to explore true regenerative potential.

That information alone is moving biotech stock investors in a big way to get behind this amazing company’s biotechnology applications of Cannabidiol.

Cannabosides for Treatment of Inflammatory Bowel Disease

Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease (IBD) patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.

But hey, don’t take our word for it.  Here’s proof:

“In this trial, cannabis induced clinical remission in 50% of patients. Taking into account that our participants had longstanding Crohn’s disease, with 80% nonresponse or intolerance to anti–TNF-a, this result is impressive.”
Naftali et. al., 2013

Role in Neuroprotection

Cannabidiol and the cannabinoid signaling pathway within the brain are involved in key aspects of both neuroprotection and brain remyelination, which is the most common regenerative process that occurs within the brain

Cannabinoid signaling molecules in the brain have been shown to be involved in oligodendrocyte maturation, which is a process thought to be critical for brain repair after being damaged by the immune system during multiple sclerosis (Gomez et. al., 2010).

Cannabidiol has been shown to been shown to protect oligodendrocyte progenitor cells, or OPCs, which are the cells that are critical for brain repair in multiple sclerosis.  In addition, it does this through methods that are entirely independent of the traditional cannabinoid signaling pathway, meaning it may exert beneficial effects in more ways than one (Mecha et. al., 2012).

That enough proof?  Now you know why biotech stock lovers are putting shares of Vitality Biopharma VBIO  in their portfolio of Biotech Stocks – and you should too!!

CHECK OUT THEIR CHART!  It’s nothing but PROGRESS, PROGRESS, PROGRESS>


The next hot biopharma stock is here!!!

showcompanylogobycompanyid

 

 

Vitality Bio PPT December 2016

Analysts Coverage and More Recent Article

 

Brandon Manns

Brandon Manns

We have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Compensation read disclaimer. http://www.financialstrend.com/disclaimer